Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

NCT02160782 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Alagille Syndrome

Interventions

DRUG: LUM001 (Maralixibat)
DRUG: Placebo

Sponsor

Mirum Pharmaceuticals, Inc.